{'fraction_non_alphanumeric': 0.04630788485607009, 'fraction_numerical': 0.041927409261576974, 'mean_word_length': 5.2952755905511815, 'pattern_counts': {'":': 0, '<': 2, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Clinical significance of weak interleukin‐35 expression in patients with psoriasis

CD4+T cells and their related cytokines play an important role in the pathogenesis of psoriasis, a chronic, recurrent, inflammatory skin disease. The role of IL‐35, an immunosuppressive cytokine involved in many autoimmune diseases, in the pathogenesis of psoriasis is unclear. In this study IL‐35 expression and its clinical significance in patients with psoriasis were evaluated. Protein and mRNA levels of specified markers were measured by ELISA and qRT‐PCR, respectively. It was found that plasma IL‐35 concentrations were lower in patients with psoriasis than in healthy individuals (Z = −6.525, P < 0.0001). mRNA titers of Ebi3 and p35 were lower in peripheral blood mononuclear cells from patients with psoriasis than in those from healthy individuals (Z = −5.078, P < 0.0001; Z = −2.609, P = 0.009, respectively). The areas under the receiver‐operating characteristic (ROC) curves for IL‐35, Ebi3 and p35 in patients with psoriasis versus controls were 0.86, 0.78 and 0.64, respectively. Pearson correlation analysis showed that, in patients with psoriasis, plasma IL‐35 expression correlated negatively with concentrations of INF‐γ, tumor necrosis factor‐alpha, IL‐23, −17, and −22, and the Psoriasis Activity and Severity Index and positively with concentrations of transforming growth factor beta and IL‐10 . In summary, IL‐35 may mediate pathogenesis of psoriasis by influencing expression of Th1/Th17/Treg‐related cytokines and may therefore be a putative target for monitoring or treating psoriasis.